Selective Androgen Receptor Modulators - Bodybuilding Supplements

Home | About SARMsDB | Advertise on SARMsDB

At this time, SARMS are NOT RECOMMENDED for human use. These drugs are still in the research and testing stages of development. In addition, some experimental drugs that are not SARMs are being marketed as or along with SARMs.
The development of Andarine (S-4) was halted because the use of this compound caused serious disturbances in vision

In 2013, the original developer discontinued GW501516 due to the discovery that during animal testing it rapidly caused cancer in multiple organs
Until such issues are resolved, DO NOT USE SARMs.

SARMs Research and Information Articles

  1. Dalton, J; “Discovery of Nonsteroidal Androgens”;  Biochemical and Biophysical Research Communications; Volume 244, Issue 1, 6 March 1998, Pages 1–4; Retrievedf rom
  2. Chen, Jiyun, Juhyun Kim, and James T. Dalton. “Discovery AND Therapeutic Promise OF Selective Androgen Receptor Modulators.” Molecular interventions 5.3 (2005): 173–188;
  3. Gao, W; Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs); Drug Discovery Today; Volume 12, Issues 5–6, March 2007, Pages 241–248; Retrieved from
  4. Cadilla, R; Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential.; Curr Top Med Chem. 2006;6(3):245-70; Retrieved from
  5. World Anti-Doping Agency; The 2015 Prohibited List; September 20, 2014; Retrieved from
  6. Hurst, M; Designer drug SRAMS sweeping world sport; The daily Telegraph; February 9, 2012; Retrieved from
  7. Singer, E; Next-Generation Sports Doping; MIT Technology Review; October 26, 2007; Retrieved from
  8. Donzé, F; WADA Executive Committee Approves the 2008 Prohibited List; September 23, 2007; Retrieved from
  9. Carroll, W; “Under the Knife”; Baseball Prospectus; February 5, 2009; Retrieved from
  10. Ligand Pharmaceuticals; Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders; Retrieved from
  11. Ligand Pharmaceuticals; Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting; November 20, 2009; Retrieved from
  12. Ligand Pharmaceuticals; Ligand Presents First-in-Human Phase I Data on Lead SARM Molecule LGD-4033 at the International Congress of Endocrinology; March 29, 2010; Retrieved from
  13. Ligand Pharmaceuticals; Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting; June 6, 2011; Retrieved from
  14. Basaria, S; Safety and Tolerability of LGD-4033, a Novel Non-Steroidal Oral Selective Androgen Receptor Modulator (SARM), in Healthy Men; Endocrine Reviews; Vol. 32 (03_MeetingAbstracts): P3-207; Retrieved from (backup abstract at
  15. Merck; GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting: Ostarine Improved Lean Body Mass and Muscle Performance in Patients with Cancer Cachexia; June 11, 2009; Retrieved from
  16. McLaughlin, K; Johnson & Johnson; Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting; May 13, 2015; Retrieved from
  17. Narayanan, Ramesh et al. “Selective Androgen Receptor Modulators in Preclinical and Clinical Development: Peer-reviewed SARMs from Johnson & Johnson (J&J) and subsidiaries.” Nuclear Receptor Signaling 6 (2008): e010; 30 Aug. 2015; Retrieved from
  18. GlaxoSmithKline; “GSK Product Development Pipeline”; March 2015; Retrieved from
  19. Narayanan, Ramesh et al. “Selective Androgen Receptor Modulators in Preclinical and Clinical Development.” Nuclear Receptor Signaling 6 (2008): e010;
  20. GTx Inc; enobosarm (Ostarine; GTx-024); Retrieved from
  21. He Y, Yin D, Perera M, Kirkovsky L, Stourman N, Li W, Dalton JT, Miller DD. Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor; European journal of medicinal chemistry. 2002; 37:619–634; Retrieved from
  22. Marhefka, Craig A. et al. “Design, Synthesis, and Biological Characterization of Metabolically Stable Selective Androgen Receptor Modulators.” Journal of medicinal chemistry 47.4 (2004): 993–998;
  23. Dalton, J; US Patent 8853266: “Selective androgen receptor modulators for treating diabetes”; April 13, 2007;
  24. US Food and Drug Administration; “Dietary Supplement Health and Education Act of 1994”; October 25, 1994; Retrieved from
  25. United States Congress; “Anabolic Steroid Control Act of 2004”; October 22, 2004; Retrieved from
  26. Zambrana, I; Food and Drug Administration; Warning Letter to BioGenix USA, LLC; December 11, 2014; Retrieved from
  27. Kloner, R; “Time course of the interaction between tadalafil and nitrates”; Journal of the American College of Cardiology; Volume 42, Issue 10, 19 November 2003, Pages 1855–1860; Retrieved from
  28. Zhi, L; “Selective androgen receptor modulators (SARMs) and uses thereof”; US Patent and Trademark Office; US Patent #8354446; Retrieved from
  29. Bigge, C; “Antidiabetic agents”; US Patent and Trademark Office; US Patent #20030171377; Retrieved from
  30. Schacht, W; Patent Law and Its Application to the Pharmaceutical Industry: An Examination of the Drug Price Competition and Patent Term Restoration Act of 1984 (“The Hatch-Waxman Act”); Congressional Research Report for Congress; January 10, 2005; Retrieved from
  31. Dalton, James T. et al. “The Selective Androgen Receptor Modulator GTx-024 (enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial.” Journal of Cachexia, Sarcopenia and Muscle 2.3 (2011): 153–161; Retrieved from
  32. Narayanan, Ramesh et al. “Selective Androgen Receptor Modulators in Preclinical and Clinical Development.” Nuclear Receptor Signaling 6 (2008); Retrieved from
  33. GTx, Inc; Form 10-Q Quarterly Report for the Quarterly Period Ended June 30, 2014; United States Securities and Exchange Commission; Retrieved from
  34. GTx, Inc; Income Statement; Google Finance; Retrieved from
  35. Geiger, L; “Rat Carcinogenicity with GW501516, a PPAR Delta Agonist”; Society of Toxicology 48th Annual Meeting and ToxExpo; The Toxicologist Supplement to Toxicological Sciences; Oxford University Press; Volume 108, Number 1, March 2009; pp. 189; Retrieved from
  36. Sahebkar, A; “New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.”; Expert Opin Pharmacother. 2014 Mar;15(4):493-503; Retrieved from
  37. World Anti-Doping Agency; “WADA issues alert on GW501516”; March 21, 2013; Retrieved from
  38. New Scientist; Anti-doping Agency Warns Athletes of Black Market Drug; March 26, 2013; Retrieved from
  39. Rossen, J; “A New Class of Unapproved Supplements Has Mass Appeal”; Maxim Magazine; April 14, 2015; Retrieved from

Comments on SARMs Research and Information Articles
No comments have been entered!

Main Navigation
  Your Link or Banner Here!
Privacy/Terms of Use | Advertise on SARMsDB | Contact SARMsDB
SARMsDB, your source for SARMs and bodybuilding supplement information